Belite Bio (BLTE) Liabilities and Shareholders Equity (2021 - 2026)

Belite Bio's Liabilities and Shareholders Equity history runs 6 years deep, the most recent figure standing at $811.3 million for Q1 2026.

• On a quarterly basis, Liabilities and Shareholders Equity rose 394.07% year-over-year to $811.3 million in Q1 2026; TTM through Mar 2026 was $2.0 billion, a 268.81% increase from a year earlier, with the FY2025 full-year figure at $780.6 million, up 413.08% from the prior year.
• Liabilities and Shareholders Equity rose to $811.3 million in Q1 2026 per BLTE's latest filing, from $780.6 million in the prior quarter.
• Across five years, Liabilities and Shareholders Equity topped out at $811.3 million in Q1 2026 and bottomed at $39.8 million in Q1 2023.
• The 5-year median for Liabilities and Shareholders Equity is $117.1 million (2024), against an average of $212.8 million.
• Biggest YoY gain for Liabilities and Shareholders Equity was 413.08% in 2025; the steepest drop was 32.07% in 2025.
• Year by year, Liabilities and Shareholders Equity stood at $44.3 million in 2022, then surged by 113.77% to $94.6 million in 2023, then jumped by 60.74% to $152.1 million in 2024, then soared by 413.08% to $780.6 million in 2025, then gained by 3.94% to $811.3 million in 2026.
• Per Business Quant, the three latest BLTE Liabilities and Shareholders Equity figures stand at $811.3 million (Q1 2026), $780.6 million (Q4 2025), and $282.4 million (Q3 2025).